These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 22522582)

  • 1. [Strategy in advanced castration-resistant prostate cancer].
    Gross-Goupil M; Roca S; Pasticier G; Ravaud A
    Bull Cancer; 2012 Jul; 99 Suppl 1():S37-45. PubMed ID: 22522582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The treatment of castration-resistant prostate cancer].
    Petrányi Á
    Magy Onkol; 2012 Dec; 56(4):219-28. PubMed ID: 23236591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New treatment options for patients with metastatic castration-resistant prostate cancer.
    Higano CS
    Cancer Treat Rev; 2012 Aug; 38(5):340-5. PubMed ID: 21944872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel molecular targets for the therapy of castration-resistant prostate cancer.
    Agarwal N; Sonpavde G; Sternberg CN
    Eur Urol; 2012 May; 61(5):950-60. PubMed ID: 22209376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities.
    Payne H; Bahl A; Mason M; Troup J; De Bono J
    BJU Int; 2012 Sep; 110(5):658-67. PubMed ID: 22429837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer.
    Vignani F; Bertaglia V; Buttigliero C; Tucci M; Scagliotti GV; Di Maio M
    Cancer Treat Rev; 2016 Mar; 44():61-73. PubMed ID: 26907461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Castration resistant prostate cancer 2011].
    Miller K
    Aktuelle Urol; 2011 Mar; 42(2):95-102. PubMed ID: 21437832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines.
    Mohler JL; Armstrong AJ; Bahnson RR; Boston B; Busby JE; D'Amico AV; Eastham JA; Enke CA; Farrington T; Higano CS; Horwitz EM; Kantoff PW; Kawachi MH; Kuettel M; Lee RJ; MacVicar GR; Malcolm AW; Miller D; Plimack ER; Pow-Sang JM; Roach M; Rohren E; Rosenfeld S; Srinivas S; Strope SA; Tward J; Twardowski P; Walsh PC; Ho M; Shead DA
    J Natl Compr Canc Netw; 2012 Sep; 10(9):1081-7. PubMed ID: 22956807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Denosumab as a promising novel bone-targeted agent in castration resistant prostate cancer.
    Dellis A; Papatsoris AG
    Expert Opin Biol Ther; 2014 Jan; 14(1):7-10. PubMed ID: 24074253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel and bone-targeted agents for CRPC.
    Fizazi K; Albiges L; Massard C; Escudier B; Loriot Y
    Ann Oncol; 2012 Sep; 23 Suppl 10():x264-7. PubMed ID: 22987974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [How to manage patients with CRPC?].
    Beuzeboc P; Massard C
    Bull Cancer; 2015 Jun; 102(6):509-15. PubMed ID: 26028494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [New hope in the treatment of advanced cancer of the prostate in 2012].
    Massard C
    Bull Cancer; 2012 Jul; 99 Suppl 1():S3. PubMed ID: 23767051
    [No Abstract]   [Full Text] [Related]  

  • 13. Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer.
    Rehman Y; Rosenberg JE
    Drug Des Devel Ther; 2012; 6():13-8. PubMed ID: 22291466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel strategies in the treatment of castration-resistant prostate cancer (Review).
    Marech I; Vacca A; Ranieri G; Gnoni A; Dammacco F
    Int J Oncol; 2012 May; 40(5):1313-20. PubMed ID: 22322981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of zoledronic acid on metastatic hormone-refractory prostate cancer resistant to taxane, estramustine, carboplatin, and dexamethasone.
    Kikuno N; Urakami S; Nakamura S; Shiina H; Igawa M
    Int J Urol; 2007 Jan; 14(1):82-4. PubMed ID: 17199867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of bone metastases in refractory prostate cancer--role of denosumab.
    Paller CJ; Carducci MA; Philips GK
    Clin Interv Aging; 2012; 7():363-72. PubMed ID: 23049248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contemporary management of metastatic castration-resistant prostate cancer.
    Sonpavde G; Sternberg CN
    Curr Opin Urol; 2011 May; 21(3):241-7. PubMed ID: 21455038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New drugs in metastatic castration-resistant prostate cancer].
    Albiges L; Loriot Y; Gross-Goupil M; de La Motte Rouge T; Blesius A; Escudier B; Massard C; Fizazi K
    Bull Cancer; 2010 Jan; 97(1):149-59. PubMed ID: 20022854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Castration-resistant prostate cancer: systemic therapy in 2012.
    Maluf FC; Smaletz O; Herchenhorn D
    Clinics (Sao Paulo); 2012; 67(4):389-94. PubMed ID: 22522765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial.
    Logothetis CJ; Basch E; Molina A; Fizazi K; North SA; Chi KN; Jones RJ; Goodman OB; Mainwaring PN; Sternberg CN; Efstathiou E; Gagnon DD; Rothman M; Hao Y; Liu CS; Kheoh TS; Haqq CM; Scher HI; de Bono JS
    Lancet Oncol; 2012 Dec; 13(12):1210-7. PubMed ID: 23142059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.